Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17259397rdf:typepubmed:Citationlld:pubmed
pubmed-article:17259397lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C1956346lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0037293lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C1708726lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0441994lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C1420799lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C0181496lld:lifeskim
pubmed-article:17259397lifeskim:mentionsumls-concept:C1522485lld:lifeskim
pubmed-article:17259397pubmed:issue2lld:pubmed
pubmed-article:17259397pubmed:dateCreated2007-1-29lld:pubmed
pubmed-article:17259397pubmed:abstractTextA20 or tumor necrosis factor (TNF)-induced protein 3 (TNFAIP3) is a negative regulator of nuclear factor-kappaB (NF-kappaB). We have investigated whether polymorphisms in this gene are associated with increased atherosclerosis in diabetic patients. Five tag single nucleotide polymorphisms (SNPs) were typed in 479 type 2 diabetic patients from Boston, including 239 coronary artery disease (CAD)-positive case subjects and 240 CAD-negative control subjects. Two tag SNPs (rs5029930 and rs610604) were independently associated with CAD; adjusted odds ratios (ORs) for minor allele carriers were 2.3 (95% CI 1.4-3.8, P = 0.001) and 2.0 (1.3-2.9, P = 0.0008), respectively. The association with rs610604 was dependent on glycemic control, with ORs of 3.9 among subjects with A1C < or =7.0% and 1.2 for those with A1C >7.0% (P for interaction = 0.015). A similar interaction pattern was found among 231 CAD-positive and 332 CAD-negative type 2 diabetic patients from Italy (OR 2.2, P = 0.05 vs. OR 0.9, P = 0.63 in the low vs. high A1C strata, P for interaction = 0.05). Quantitative RT-PCR in blood mononuclear cells from 83 nondiabetic subjects showed that rs610604 and rs5029930 minor allele homozygotes have 30-45% lower levels of A20 mRNA than major allele homozygotes, and heterozygotes have intermediate levels (P = 0.04 and 0.028, respectively). These findings point to variability in the A20/TNFAIP3 gene as a modulator of CAD risk in type 2 diabetes. This effect is mediated by allelic differences in A20 expression.lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:languageenglld:pubmed
pubmed-article:17259397pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17259397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17259397pubmed:statusMEDLINElld:pubmed
pubmed-article:17259397pubmed:monthFeblld:pubmed
pubmed-article:17259397pubmed:issn0012-1797lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:Boonyasrisawa...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:TrischittaVin...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:ShoelsonSteve...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:DoriaAlessand...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:BacciSimonett...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:ZhangYuan-Yua...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:NolanDavidDlld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:JohnstoneMich...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:GervinoErnest...lld:pubmed
pubmed-article:17259397pubmed:authorpubmed-author:EberleDelphin...lld:pubmed
pubmed-article:17259397pubmed:issnTypePrintlld:pubmed
pubmed-article:17259397pubmed:volume56lld:pubmed
pubmed-article:17259397pubmed:ownerNLMlld:pubmed
pubmed-article:17259397pubmed:authorsCompleteYlld:pubmed
pubmed-article:17259397pubmed:pagination499-505lld:pubmed
pubmed-article:17259397pubmed:dateRevised2011-2-3lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:meshHeadingpubmed-meshheading:17259397...lld:pubmed
pubmed-article:17259397pubmed:year2007lld:pubmed
pubmed-article:17259397pubmed:articleTitleTag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes.lld:pubmed
pubmed-article:17259397pubmed:affiliationSection on Genetics and Epidemiology, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA.lld:pubmed
pubmed-article:17259397pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17259397pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17259397pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:7128entrezgene:pubmedpubmed-article:17259397lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17259397lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17259397lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17259397lld:pubmed